Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 2Phase NA 1Phase 1/2 1

Status

Recruiting 3Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Tumor-Agnostic 3Sarcoma 1Plasma cell 1Lymphoid 1Breast 1

Conditions

Breast Neoplasms 13Triple Negative Breast Neoplasms 7Prostatic Neoplasms 7Neoplasms 6Ovarian Neoplasms 4Neoplasm Metastasis 4Endometrial Neoplasms 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Prostatic Diseases 1Prostate Cancer Metastatic 1Premenopausal HR+/HER2- Metastatic Breast Cancer 1Pheochromocytoma 1Pathologic Complete Response 1Paraganglioma 1Pancreatic Neoplasms 1Multiple Myeloma 1Mesothelioma, Malignant 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Hemangiosarcoma 1Glioma 1Glioblastoma 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Extensive Stage Lung Small Cell Carcinoma 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × talazoparib × Clear all
NCT02693535 2026-05-29

TAPUR

American Society of Clinical Oncology

Phase 2 Recruiting
4,200 enrolled
LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT02286687 2026-01-02

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
150 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT05097599 2025-01-08

StrataPATH

Strata Oncology

Phase 2 Terminated
11 enrolled
Tumor-Agnostic

Neoplasms

NCT02925234 2024-01-24

DRUP

The Netherlands Cancer Institute

Phase 2 Recruiting
1,550 enrolled
Tumor-Agnostic

Neoplasms

NCT02921919 2022-08-24

Open-Label Extension and Safety Study of Talazoparib

Pfizer

Phase 2 Completed
120 enrolled 16 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡